Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (11): 20-26.doi: 10.6040/j.issn.1671-7554.0.2018.1470

Previous Articles    

Clinical effect of gefitinib combined with chemotherapy on patients with advanced non-small cell lung cancer

WANG Jianli1, WANG Xiaojing2, SUN Yulian3, HU Xiaole4, LUAN Xiaorong5   

  1. 1. Department of Respiratory Medicine;
    2. Department of ENT;
    3. Department of Hepatology;
    4. Operation Room;
    5. Nursing Department, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-09-27

PDF (PC)

3

Abstract: Objective To observe the efficacy of gefeitinib combined with chemotherapy on the advanced non-small cell lung cancer(NSCLC)patients, and to compare the changes of serum carcinoembryonic antigen(CEA), neuron-specific enolase(NSE), squamous cell cancer-related antigen(SCC)and disease control rate before and after treatment. Methods A total of 100 lung adenocarcinoma patients with epidermal growth factor receptor(EGFR)mutation-positive were divided into observation group(n=50)and control group(n=50)according to different treatment regimens. The observation group was treated with pemetrexed + carboplatin combined with gefeitinib, and the control group was treated with pemetrexed + carboplatin for 4 cycles to evaluate the clinical efficacy and the changes of CEA, NSE and SCC in the serum of patients, as well as to compare the difference in progression-free survival(PFS)between the two groups. Results Compared with the control group, the objective effective rate(60.0% vs 36.0%, χ2=5.769, P=0.027)and disease control rate(86.0% vs 66.0%, χ2=5.482, P=0.034)were higher. After treatment, the levels of CEA and NSE in serum decreased compared with those before treatment in both groups(t=-10.370, P<0.001; t=-4.802, 山 东 大 学 学 报 (医 学 版)57卷11期 -王建丽,等.吉非替尼联合化疗治疗50例晚期非小细胞肺癌患者的疗效 \=-P<0.001). The median PFS in the observation group was longer than that in the control group(10.9 months vs 7.9 months, χ2=45.183, P<0.001). The COX multivariate analysis showed that smoking history, ECOG score and case grouping had statistical significance on PFS. The median PFS of patients without smoking history was longer than those with smoking history(HR=1.929, 95%CI: 1.126-3.306, P=0.017); the median PFS of patients with ECOG scores being 0-1 was longer than those with ECOG scores≥2(HR=2.059, 95%CI: 1.267-3.348, P=0.004); the median PFS of patients in the observation group(HR=0.195, 95%CI)is longer than those in the control group(HR=0.195, 95%CI:0.118-0.320,P=0.001). The incidence of adverse reactions in the observation group was higher than those in the control group without the statistical difference(46.0% vs 36.0%, χ2=1.033, P=0.309). Conclusion Gefitinib combined with chemotherapy is effective in the treatment of advanced NSCLC patients with better disease control rate, decreased serum CEA and NSE levels and prolonged PFS of patients. The method is safe and has fewer adverse reactions, worthy of promoting clinically.

Key words: Gifitinib, Non-small cell lung cancer, Target biotherapy, Epidermal growth factor receptor

CLC Number: 

  • R734.2
[1] Xiao HQ, Tian RH, Zhang ZH, et al. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis[J]. Onco Targets Ther, 2016, 9: 1471-1476. doi: 10.2147/OTT.S96160.
[2] 李为民,赵爽,刘伦旭.肺癌早期诊断方法及临床意义[J].四川大学学报(医学版), 2017, 48(3): 331-335. LI Weimin, ZHAO Shuang, LIU Lunxu. The methods and clinical significance of early diagnosis of lung cancer[J]. Journal of Sichuan University(Medical Science Edition), 2017, 48(3): 331-335.
[3] Qin HF, Qu LL, Liu H, et al. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 2013, 14(7): 4205-4208.
[4] 周欣,李晓琴,王秀丽,等.吉非替尼获得性耐药的非小细胞肺癌患者临床特点[J].中国癌症杂志, 2015, 25(3): 222-230. ZHOU Xin, LI Xiaoqin, WANG Xiuli, et al. The treatment for acquired drug resistance of clinical characteristics of patients with non-small cell lung cancer[J]. China Oncology, 2015, 25(3): 222-230.
[5] 曾越灿,蔡炜嵩,吴荣,等.厄洛替尼治疗终末期非小细胞肺癌的疗效观察[J].疑难病杂志, 2014, 13(3): 278-280, 283. ZENG Yuecan, CAI Weisong, WU Rong, et al. Efficacy of erlotinib in treatment of end-stage non-small cell lung cancer[J]. Chinese Journal of Difficult and Complicated Cases, 2014, 13(3): 278-280, 283.
[6] 王光辉,许阳,刘勇谋,等.表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌临床观察[J].疑难病杂志, 2014, 13(7): 686-689, 693. WANG Guanghui, XU Yang, LIU Yongmou, et al. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitor to treat patients with advanced non-small cell lung cancer[J]. Chinese Journal of Difficult and Complicated Cases, 2014, 13(7): 686-689, 693.
[7] Chen G, Kronenberger P, Teugels E, et al. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents[J]. Biochem Biophys Res Commun, 2013, 431(3): 623-629.
[8] Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lungcancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
[9] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[10] 张坦,王艺曈,方翼.非小细胞肺癌靶向治疗药物的研究现状[J].中国临床药理学杂志, 2017, 33(11): 1054-1057. ZHANG Tan, WANG Yitong, FANG Yi. Research status of targeted agents for the treatment of non-small cell lung cancer[J]. The Chinese Journal of Clinical Pharmacology, 2017, 33(11): 1054-1057.
[11] 周荻,徐欣,谢华英,等.全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移疗效分析[J].上海交通大学学报(医学版), 2013, 33(4): 480-484. ZHOU Di, XU Xin, XIE Huaying, et al. Therapeutic effects of whole brain radiotherapy with targeted therapy and concomitant chemo-radiotherapy in treatment of non-small-cell lung cancer with brain metastasis[J]. Journal of Shanghai Jiaotong University(Medical Science), 2013, 33(4): 480-484.
[12] 孙燕,吴一龙,李龙芸,等.吉非替尼或多西他赛治疗一线化疗失败的非小细胞肺癌的临床分析[J].中华肿瘤杂志, 2011, 33(5): 377-380. SUN Yan, WU Yilong, LI Longyun, et al. Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer(NSCLC )who had failed previous platinum-based first-line chemotherapy[J]. Chinese Journal of Oncology, 2011, 33(5): 377-380.
[13] 曹新广,吕慧芳,陈贝贝,等.Axl调控的 miRNA 表达在NSCLC 吉非替尼获得性耐药中的意义[J].郑州大学学报(医学版), 2015, 50(5): 651-655, CAO Xinguang, LV Huifang, CHEN Beibei, et al. Axl-modulated miRNA regulates gefitinib-resistance in lung cancer[J]. Journal of Zhengzhou University(Medical Sciences), 2015, 50(5): 651-655.
[14] 陈红,张瑞虹,杜改萍,等.三维适形放疗联合吉非替尼治疗老年非小细胞肺癌的疗效[J].中国老年学杂志, 2011, 31(21): 4131-4132.
[15] Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 371(21): 1963-1971.
[16] 谢亚琳,梁继珍,苏宁.吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J].南方医科大学学报, 2015, 35(3): 446-449. XIE Yalin, LIANG Jizhen, SU Ning. Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer[J]. Journal of Southern Medical University, 2015, 35(3): 446-449.
[17] 谢厚耐,李猛,许林,等.吉非替尼对比培美曲塞联合顺铂治疗术后EGFR突变阳性Ⅱ~Ⅲ A 期肺腺癌的临床分析[J].山东大学学报(医学版), 2018, 56(9): 29-34. XIE Hounai, LI Meng, XU Lin, et al. Clinical analysis of gefitinib versus pemetrexed combined with cisplatin in patients with stage Ⅱ-Ⅲ A lung adenocarcinoma harbouring positive EGFR mutations[J]. Journal of Shandong University(Health Sciences), 2018, 56(9): 29-34.
[18] Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)[J]. J Clin Oncol, 2011, 29(21): 2866-2874.
[19] Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2): a randomised, double-blind trial[J]. Lancet Oncol, 2013, 14(8): 777-786.
[20] 江冠铭,贾筠,谭钦全,等.化疗交替吉非替尼治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的效果[J].广东医学, 2015, 36(11): 1757-1760.
[21] Dai L, Qu Y, Li J, et al. Serological proteome analysis ap-proach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small celllung cancer[J]. Oncotarget, 2017, 8(22): 36664-36673.
[22] 陈宝,邢福军.6种肿瘤标志物联合检测在肺癌诊疗中的价值[J].西部中医药, 2017, 30(8): 158-160. CHEN Bao, XING Fujun. The value of combined detection of six tumor markers in the diagnosis and treatment of lung cancer[J]. Western Journal of Traditional Chinese Medicine, 2017, 30(8): 158-160.
[23] 杨兰平,黄汉生,陈慧华,等.非小细胞肺癌患者化疗前后血清CYFRA211、CEA、NSE、CA125、CA199水平的变化及临床意义[J].实用临床医药杂志, 2014, 18(17): 40-43. YANG Lanping, HUANG Hansheng, CHEN Huihua, et al. Clinical significance in changes of serum CYFRA211, CEA, NSE, CA125, CA199 levels before and after chemotherapy in patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2014, 18(17): 40-43.
[24] 杨卫京,牛东,王辉.肺癌患者化疗前后血清CYFRA21-1、NSE和CA125水平的变化及意义[J].医学综述, 2017, 23(20): 4150-4153. YANG Weijing, NIU Dong, WANG Hui. Changes and significance of serum, CYFRA21-1, NSE and CA125 levels in patients with lung cancer before and after chemotherapy[J]. Medical Recapitulate, 2017, 23(20): 4150-4153.
[25] Holdenrieder S, Wehnl B, Hettwer K, et al. Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis[J]. Br J Cancer, 2017, 116(8): 1037-1045.
[26] Liang J, Qian Y, Xu D, et al. Serum tumor markers, hypoxia-inducible factor-1α HIF-1α and vascular endothelial growth factor,in patients with non-small cell lung cancer before and after intervention[J]. Asian Pac J Cancer Prev, 2013, 14(6): 3851-3854.
[27] Facchinetti F, Aldigeri R, Aloe R, et al. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients[J]. Tumour Biol, 2015, 36(8): 5943-5951.
[28] 潘世扬.肺癌疗效评价标志物的研究进展[J].山东大学学报(医学版), 2018, 56(10): 31-39. PAN Shiyang. Research advances in markers for the evaluation of lung cancer efficacy[J]. Journal of Shandong University(Health Sciences), 2018, 56(10): 31-39.
[29] 闫存玲,郭子健.肺癌实验室诊断专家共识[J].山东大学学报(医学版), 2018, 56(10): 9-17. YAN Cunling, GUO Zijian. Expert consensus on laboratory diagnosis of lung cancer[J]. Journal of Shandong University(Health Sciences), 2018, 56(10): 9-17.
[30] 卡哈尔江·阿不都外力,李晓琴,刘春玲.化疗前后肺癌肿瘤标记物水平的变化及其临床价值[J].新疆医科大学学报, 2014, 37(1): 93-96. Kahaerjiang Abuduwaili, LI Xiaoqin, LIU Chunling. Changes of levels of tumor markers in patients with lung cancer before and after chemotherapy and its clinical significance[J]. Journal of Xinjiang Medical University, 2014, 37(1): 93-96.
[31] Fizazi K, Cojean I, Pignon JP, et al. Normal serum neu- ron specific enolase(NSE)value after the first cycle of chemotherapy[J]. Cancer, 2015, 82(6):1049-1055.
[32] 谢刚强,刘春田,张永庆,等.吉非替尼治疗非小细胞肺癌患者的临床疗效分析[J].现代生物医学进展,2016, 16(34): 6754-6757. XIE Gangqiang, LIU Chuntian, ZHANG Yongqing, et al. Effects of gefitinib on the serum and bronchial velar lavage fluid CA125,CEA and MMP-9 levels and clinical efficacy of patients with lung cancer[J]. Progress in Modern Biomedicine, 2016, 16(34): 6754-6757.
[33] 胡杨,杨玲,魏友英.培美曲塞联合吉非替尼对中老年晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].中国老年学杂志, 2018, 38(23): 5705-5707.
[1] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[2] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[3] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[4] WEI Ping, DU Lutao, WANG Qing, ZHAN Yao, XIE Yujiao, ZHANG Shujun, DUAN Weili, WANG Chuanxin. Diagnostic value of serum exosomal miR-20b-5p for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 91-96.
[5] WANG Wei, LIU Yongzheng, LI Ling. Effects of Physalin B on proliferation, migration and apoptosis of human non-small cell lung cancer cells [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 13-18.
[6] ZHENG Qingyue, ZHAO Qiuhong, QU Xiangyun, DONG Zhaonan, MA Xueqing, JIA Yunli. Diagnosis value of serum exosome miR-205-5p/miR-152-5p on early non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 101-106.
[7] XU Shuyuan, JI Quanjiang, GUO Li. Effects of serum levels of sEGFR, CEA and Cyfra21-1 on the prognosis of non-small cell lung cancer patients [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 107-111.
[8] SHI Shuyuan, GUAN Zhiyu, SUN Daqiang. Recombinant human vascular endostatin enhances antitumour activity of EGFR-TKIs for lung cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 6-10.
[9] XIE Hounai, LI Meng, XU Lin, WANG Hui, PENG Yue, PENG Zhongmin. Clinical analysis of gefitinib versus pemetrexed combined with cisplatin in patients with stage Ⅱ-ⅢA lung adenocarcinoma harbouring positive EGFR mutations [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 29-34.
[10] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[11] PENG Yue, FENG Zhen, XIE Hounai, WANG Hui, LI Meng, REN Wangang, LIU Tong, PENG Zhongmin. Surgical treatment for 61 patients with multiple lung lesions [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 42-46.
[12] WANG Lili, HUO Bin, WANG Lei, WANG Hao, HOU Dingkun, HUO Xiaodong, WANG Jinhuan, ZANG Li, CAO Qiang, CHAI Shude, WANG Haitao. Meta-analysis and system evaluation of 125I implantation in the treatment of early lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 76-83.
[13] GAO Ang, WANG Shijiang, FU Zheng, SUN Xindong, YU Jinming, MENG Xue. A feasibility study for boost target delineation using 18F-FDG PET/CT in local advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 73-77.
[14] YANG Lu, LIU Yanguo, LI Jisheng, WANG Xiuwen. Effect of bufalin on chemosensitivity to cisplatin in non-small cell lung cancer and the underlying mechanisms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 6-11.
[15] GAO Peng, SHEN Fangzhen, XIAO Wenjing, XIU Yuande, ZHOU Lingling. Correlation between the expressions of Runx2 and Ezrin and postoperative metastasis in patients with stage IB non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 63-66.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd